Vorasidenib, a brain-penetrant dual inhibitor of mutant IDH1 and IDH2 enzymes, enhanced progression-free survival of patients with residual or recurrent grade 2 IDH-mutant glioma (NCT04164901) [62,63]. Here, IDH2 is linked to central nervous system cancer.